证券之星消息，截至2025年12月15日收盘，奥精医疗(688613)报收于20.02元，上涨1.93%，换手率 2.95%，成交量4.04万手，成交额8058.3万元。 12月15日的资金流向数据方面，主力资金净流入176.3万元，占总成交额2.19%，游资资金净流入234.26 万元，占总成交额2.91%，散户资金净流出410.56万元，占总成交额5.09%。 近5日资金流向一览见下表： | 指标 | 跑精医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 27.43亿元 | 107.5亿元 | 110 125 | | 净资产 | 14.49亿元 | 38.83亿元 | 88 125 | | 净利润 | 1394.06万元 | 2.1亿元 | 89 125 | | 市盈率(动) | 147.57 | 73.47 | 82 125 | | 市净率 | 1.91 | 3.77 | 36 125 | | 毛利率 | 68.9% | 51.02% | 24 125 | | 净利率 | 6.79% | 9.59% | 73 125 | | ROE | 0 ...

近5日融资融券数据一览见下表： 证券之星消息，截至2025年9月17日收盘，奥精医疗(688613)报收于27.8元，下跌2.52%，换手率 7.11%，成交量9.74万手，成交额2.71亿元。 9月17日的资金流向数据方面，主力资金净流入2625.12万元，占总成交额9.68%，游资资金净流出 954.34万元，占总成交额3.52%，散户资金净流出1670.78万元，占总成交额6.16%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-17 | 27.80 -2.52% | | 2625.12万 | 9.68% | -954.34万 | -3.52% | -1670.78万 | -6.16% | | 2025-09-16 | 28.52 | 6.78% | -1487.58万 | -3.13% | 1582.69万 | 3.33% | -95.11万 | -0.20% | | ...

Core Viewpoint - The stock of Aojing Medical (688613) has experienced a decline of 4.4% as of September 10, 2025, closing at 25.42 yuan, with significant net outflows from major funds and a mixed performance from retail investors [1][2]. Financial Performance - Aojing Medical reported a main revenue of 100 million yuan for the first half of 2025, a year-on-year decrease of 0.2% [5]. - The net profit attributable to shareholders was 7.9753 million yuan, down 13.52% year-on-year [5]. - The second quarter of 2025 showed a single-quarter main revenue of 57.5772 million yuan, an increase of 8.88% year-on-year, and a net profit of 6.9338 million yuan, up 203.59% year-on-year [5]. Market Activity - On September 10, 2025, the stock had a trading volume of 134,700 hands and a transaction amount of 341 million yuan [1]. - The net outflow of major funds was 45.0152 million yuan, accounting for 13.21% of the total transaction amount, while retail investors saw a net inflow of 33.3271 million yuan, representing 9.78% of the total [1][2]. Financing and Margin Trading - As of September 10, 2025, the financing balance was 178 million yuan, with a net financing purchase of 2.518 million yuan [3]. - There were no short selling activities reported on that day, indicating a stable margin trading environment [3]. Industry Comparison - Aojing Medical's total market capitalization is 3.483 billion yuan, significantly lower than the industry average of 12.107 billion yuan, ranking 97 out of 123 in the medical device sector [5]. - The company's gross margin stands at 63.12%, which is above the industry average of 51.85%, ranking 42 out of 123 [5].

Group 1 - The stock of Aojing Medical (688613) closed at 21.5 yuan on September 5, 2025, with an increase of 9.19% and a turnover rate of 6.38% [1] - The net inflow of main funds on September 5 was 2.77 million yuan, accounting for 1.52% of the total turnover, while retail investors had a net inflow of 7.08 million yuan, accounting for 3.90% [1] - Over the past five days, the stock has experienced fluctuations in fund flows, with notable changes in retail and main fund activities [1][2] Group 2 - Aojing Medical's financing data shows a net purchase of 8.74 million yuan on September 5, with a total financing balance of 158 million yuan [2] - The company's main business revenue for the first half of 2025 was 100 million yuan, a year-on-year decrease of 0.2%, while the net profit attributable to shareholders was 7.98 million yuan, down 13.52% year-on-year [4] - The company reported a gross profit margin of 63.12% and a net profit margin of 5.53%, indicating a relatively strong profitability compared to industry averages [4] Group 3 - Aojing Medical's total market value is 2.946 billion yuan, significantly lower than the industry average of 11.933 billion yuan [4] - The company ranks 90th in net profit within the medical device industry, with a net profit of 7.98 million yuan compared to the industry average of 149 million yuan [4] - The company's price-to-earnings ratio (184.67) is considerably higher than the industry average (65.4), indicating potential overvaluation [4]

Core Viewpoint - The stock of Aojing Medical (688613) has shown a recent increase in price, with a closing price of 20.26 yuan on August 8, 2025, reflecting a rise of 2.22% [1] Financial Performance - Aojing Medical reported a main revenue of 42.46 million yuan for Q1 2025, representing a year-on-year decline of 10.35% [5] - The net profit attributable to shareholders was 104.15 thousand yuan, down 84.99% year-on-year [5] - The company’s gross profit margin stood at 60.71%, which is higher than the industry average of 51.35% [5] Market Activity - On August 8, 2025, the net inflow of main funds was 16.87 million yuan, accounting for 12.36% of the total transaction amount [1] - Retail investors experienced a net outflow of 10.45 million yuan, representing 7.65% of the total transaction amount [1] - The stock's turnover rate was 4.93%, with a total transaction amount of 136 million yuan [1] Financing and Margin Trading - On August 8, 2025, the financing balance was 138 million yuan, with a net purchase of 6.56 million yuan [3] - The company had no short selling activity, with a margin balance of 138 million yuan [3] Industry Comparison - Aojing Medical's total market capitalization is 2.776 billion yuan, significantly lower than the industry average of 11.731 billion yuan [5] - The company has a price-to-earnings ratio of 666.29, which is substantially higher than the industry average of 65.84 [5] - The return on equity (ROE) for Aojing Medical is 0.07%, compared to the industry average of 1.15% [5]